Prostazan-Vista kaps. it is firm. 0.4 mg No. 30

Capsules with the modified release of "Prostazan-Vista" are used to treatment of functional disorders from the lower uric ways in a benign hyperplasia of a prostate.

Structure

Active ingredient - a tamsulozina a hydrochloride (one capsule contains 0.4 mg of a tamsulozin of a hydrochloride).

Excipients: cellulose microcrystalline, dispersion of 30% methacrylate acids - ethylacrylate copolymer (1:1), the containing polysorbate 80 (about 2.8%), sodium lauryl sulfate (about 0.7%), triethyl citrate, talc.

Covering of pellets: dispersion of 30% methacrylate acids - ethylacrylate copolymer (1:1), the containing polysorbate 80 (about 2.8%), sodium lauryl sulfate (about 0.7%), talc, triethyl citrate.

Structure of the capsule: gelatin, indigotin (E 132), titan dioxide (E 171), ferrous oxide yellow (E 172), ferrous oxide red (E172), ferrous oxide black (E 172).

Contraindication

• hypersensitivity to a hydrochloride tamsulozin, including the medicinal induced Quincke's disease, or to any of excipients;
• existence in the anamnesis of orthostatic hypotension;
• heavy liver failure.

Route of administration

Recommended dose for adults - one capsule daily after a breakfast or after the first meal. To swallow the capsule entirely, not to break and not to chew as it will interfere with the modified release of active ingredient.

Pregnant

Drug is not shown by

Feature of use

during clinical trials of a tamsulozin during the short and long time noted disturbances of an ejaculation. Cases of disturbance of an ejaculation, a retrograde ejaculation and an insufficient ejaculation were noted during the postregistration period.

Children

not to use Drug to children. Safety and efficiency of use of a tamsulozin to children up to 18 years were not estimated.

Drivers

. However, patients have to be warned about possibility of drowsiness, turbidity of sight, dizziness and faint.

Overdose

Symptoms

Overdose of a tamsulozin a hydrochloride can potentially cause heavy hypotensive action. Heavy hypotensive action was noted at various extents of overdose.

Treatment

in case of sharp pressure decrease owing to overdose the maintenance therapy directed to restoration of normal function of a cardiovascular system (for example, the patient has to accept horizontal position). If this measure does not work, to carry out infusional therapy and to appoint angiotonic means. It is necessary to monitor function of kidneys and to carry out the general maintenance therapy. Considering high extent of linking of a tamsulozin with proteins of plasma it is improbable that carrying out a hemodialysis is reasonable.

for the purpose of the termination of further absorption of medicament can cause vomiting artificially. At overdose of a significant amount of medicament the patient needs to wash out a stomach using activated carbon and low-osmotic depletive, such as sodium sulfate.

Side effects

Neurologic disorders: often (> 1/100, <1/10) - dizziness (1.3%); infrequently (> 1/1000, <1/100) - a headache; seldom (> 1/10000, <1/1000) - a syncope.

from an organ of sight: it is unknown (it is impossible to estimate on the available available data) - misting of sight, a disorder of vision.

from heart: infrequently (> 1/1000, <1/100) - heart consciousness.

Vascular disorders: infrequently (> 1/1000, <1/100) - orthostatic hypotension.

Respiratory and mediastinal disorders: infrequently (> 1/1000, <1/100) - rhinitis; it is unknown (it is impossible to estimate on the available available data) - nasal bleeding.

Gastrointestinal disorders: infrequently (> 1/1000, <1/100) - a constipation, diarrhea, nausea, vomiting; it is unknown (it is impossible to estimate on the available available data) - dryness in a mouth.

from skin and mucous membranes: infrequently (> 1/1000, <1/100) - rash, an itching, urticaria; seldom (> 1/10000, <1/1000) - a Quincke's disease; very seldom (<1/10000) - Stephens-Johnson's syndrome; it is unknown (it is impossible to estimate on the available available data) - a multiformny erythema, exfoliative dermatitis.

Reproductive disturbances: often (> 1/100, <1/10) - ejaculation disorders, including a retrograde ejaculation and insufficiency of an ejaculation; very seldom (<1/10000) - a priapism.

during postregistration supervision described cases of intraoperative instability of an iris of the eye of an eye (syndrome of a miotic pupil) at operation for a cataract and glaucoma at the patients accepting tamsulozin.

Postregistration experience. Except the above-stated side reactions, it was reported about cases of fibrillation of auricles, arrhythmia, tachycardia and dispnoe. As about the specified cases it was reported spontaneously, the frequency of messages and a role of a tamsulozin at the same time cannot be established authentically.

to Store

in original packing at a temperature not above 25 °C, out of children's reach.

Expiration date - 3 years.